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ARTICLEVIEW AND REVIEW
Guidelines for the diagnosis, treatment and 
clinical monitoring of patients with juvenile 
and adult Pompe disease
Diretriz para o diagnóstico, tratamento e acompanhamento clínico de pacientes com 
doença de Pompe juvenil e do adulto
Juan Clinton Llerena Junior1, Osvaldo JM Nascimento2, Acary Souza B Oliveira3, Mario Emilio T Dourado Junior4, 
Carlo D Marrone5, Heloise Helena Siqueira6, Cláudia F R Sobreira7, Elza Dias-Tosta8, Lineu Cesar Werneck9
Data collection 
This study began in 2013 with a web search on the da-
tabases Medline, Embase and LILACS using the following 
keywords: “Glycogen Storage Disease Type II” [MeSH] 
OR “Lysosomal Storage Diseases” [MeSH] OR “Pompe 
Disease” [MeSH] OR “Enzymatic Replacement Therapy” 
[MeSH]. We obtained 255 studies, 123 for childhood onset 
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abstract
Pompe disease (PD) is a potentially lethal illness involving irreversible muscle damage resulting from glycogen storage in muscle fiber 
and activation of autophagic pathways. A promising therapeutic perspective for PD is enzyme replacement therapy (ERT) with the human 
recombinant enzyme acid alpha-glucosidase (Myozyme®). The need to organize a diagnostic flowchart, systematize clinical follow-up, 
and establish new therapeutic recommendations has become vital, as ERT ensures greater patient longevity. A task force of experienced 
clinicians outlined a protocol for diagnosis, monitoring, treatment, genetic counseling, and rehabilitation for PD patients. The study was 
conducted under the coordination of REBREPOM, the Brazilian Network for Studies of PD. The meeting of these experts took place in 
October 2013, at L’Hotel Port Bay in São Paulo, Brazil. In August 2014, the text was reassessed and updated. Given the rarity of PD and 
limited high-impact publications, experts submitted their views.
Keywords: Pompe disease, glycogen storage disease type II, acid alpha-glucosidase, muscular weakness, dyspnea, GAA gene, rhGAA.
resUMo
A doença de Pompe (DP) é uma doença grave, potencialmente letal, devida ao depósito de glicogênio na fibra muscular e ativação de vias autofágicas. 
Tratamento promissor para a DP é a reposição enzimática com a enzima recombinante humana alfa-glicosidase ácida (rhAGA - Myozyme®). A 
necessidade de organizar uma propedêutica diagnóstica, sistematizar o seguimento clínico e sedimentar as novas recomendações terapêuticas 
tornaram-se vitais à medida que o tratamento permite uma maior longevidade aos pacientes. Uma força-tarefa de  clínicos experientes no manejo 
da DP foi constituída para elaborar um  protocolo para o diagnóstico, acompanhamento clínico, tratamento, aconselhamento genético, entre 
outras considerações voltadas ao paciente adulto. O estudo foi realizado sob a coordenação da Rede Brasileira de Estudos da Doença de Pompe 
(REBREPOM).  Diante da raridade da DP e escassez de trabalhos de alto impacto de evidência científica, os especialistas emitiram suas opiniões.
Palavras-chave: doença de Pompe, doença de depósito de glicogênio tipo II, alfa-glicosidade ácida, debilidade muscular, dispneia, gene 
GAA, GAA recombinante humana.
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(< 18 years old) Pompe Disease (PD) and 132 for adult on-
set PD. We then selected studies based on their strength of 
recommendation and quality of evidence. In August 2014, 
a new search identified 329 studies published between the 
years 2010 and 2014.
Strength of recommendation and quality of evidence: 
A. experimental studies or strong observational studies 
(randomized);B. experimental studies or other observational 
studies (case-control); C. Case reports (uncontrolled studies); 
D. expert opinion without critical evaluation, based on con-
sensus, physiological studies or animal models.
PD Definition
Pompe disease (PD) (OMIM # 232300), also known as 
glycogen storage disease type II, is a rare lysosomal storage 
disease classified as an inborn error of metabolism1. It is 
caused by partial or complete deficiency in the activity of the 
acid alpha-glucosidase enzyme (GAA) (EC 3.2.1.20), which is 
essential for the degradation of lysosomal glycogen into glu-
cose. This deficiency causes a progressive accumulation of 
glycogen in the cells of various tissues, manifesting in mul-
tisystem form, predominantly in the skeletal, cardiac and 
smooth muscle systems1.
PD has been defined as a low/abnormal activity of the 
GAA enzyme in asymptomatic or symptomatic individu-
als and/or presence of two pathogenic mutations in the 
GAA gene2 (B).
ePiDeMioloGy
The frequency of PD is quite variable (Table1). Recently, 
through a blind analysis of 100,000 samples obtained from 
neonatal screening through mass tandem spectrometry, 
Scott  et  al.3 (B) identified, among other lysosomal diseases 
(Fabry and mucopolysaccharidosis type 1 - MPS I), an inci-
dence of PD about 1/27,800 of the newborns.
On the other hand, a study conducted in 104 muscle biop-
sies from asymptomatic or oligosymptomatic ( fatigue, cramps, 
myalgia) patients, with increased serum CK, normal physical 
examination and no statin exposure, PD in juvenile and adults 
(PDJ-A) was identified in 3.8% of patients4 (C). Werneck et al.5, in 
a particular study of symptomatic cases, reviewed 4,500 muscle 
biopsies performed over a period of 33 years in a reference cen-
ter for neuromuscular diseases in Brazil and identified 19 cases 
of PD, 10 cases of early onset PD and 9 cases of PDJ-A (C).
PathoPhysiology
PD is an autosomal recessive disease caused by patho-
genic mutations in both copies of the gene that encodes the 
enzyme GAA. Hundreds of mutations have been identified in 
the GAA gene (http://www.pompecenter.nl/).
PD severity and age of symptom onset are related to the 
level of residual activity of the GAA enzyme. Early onset in-
fantile PD results from a complete deficiency of the enzyme 
(activity < 1%), while late onset PD (juvenile or adult) results 
from partial deficiency of GAA (1-30%). Onset may occur as 
early in childhood or as late as at the sixth decade of life6,7 (B).
The cause of PD is the progressive accumulation of in-
tralysosomal glycogen due to the inability of the cell to 
breakdown the lysosomal glycogen into glucose. As a result, 
lysosomal membranes rupture, causing leakage of hydrolytic 
material into the cytoplasm with impairment of the muscle 
contractile unit1. There is also saturation of autophagic path-
ways during the pathophysiological process8 (C).
syMPtoMs anD siGns of jUvenile anD aDUlt 
PoMPe Disease (table2)
The clinical manifestations vary according to the pa-
tient’s age, the rate of disease progression and the extent of 
organ involvement, and may result in irreversible motor im-
pairment9,10 (B). The most common manifestation in adults is 
progressive muscle weakness simulating the muscular dystro-
phies. Most patients present weakness of the proximal and ax-
ial musculature, especially in the lower limbs14,15 (C). Weakness 
of the paraspinal muscles of the lower back, weak and protrud-
ing abdominal muscles, weakness of facial muscles and eyelid 
ptosis and tongue paralysis reinforce the clinical suspicion11,12,13.
The presence of dysphonia and dysphagia reflects the dis-
ease’s bulbar impairment14, and involvement of the auditory 
system has also been reported15.
GUiDeD Physical exaMination
The physical examination in PDJ-A should focus on the 
muscular and respiratory systems.
Table 1. Pompe disease incidence in different populations.
Population (Year) Incidence Reference
Afro-Americans (2001) 1: 14,000 1
Dutch (1999) 1: 40,000 combined
1: 138,000 early onset
1: 57,000 adults
4
Americans (1998) 1: 40,000 combined 5
European Descendents 
(1998)
1:100,000 early onset
1: 60,000 adults
5
Australia (1999) 1: 145,000 6
Portugal (2004) 1: 600,000 7
Taiwan (2014)* 1:18.221 combined
1:52.538 early onset
1:27.866 late onset
8
*neonatal screening.
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Pain and fatigue are regularly reported symptoms16. 
Diaphragm muscle weakness occurs early on in PD, and may 
precede limb or axial muscle weakness17 (B).
In a patient that is asymptomatic or has muscle fatigue, 
the following signs and symptoms may be seen in PDJ-A:
• compensatory rotation of the body to rise from 
the ground11 (C);
• morning headache; narcolepsy17 (C);
• myopathy with myotonic paroxystic discharges (as seen 
in EMG) without clinical myotonia18 (C);
• CK levels that do not exceed 15 times the normal value4 (C);
• increased transaminases without liver disease in asymp-
tomatic or oligosymptomatic individuals19 (C);
• vacuolar myopathy assessed by muscular biopsy5 (C);
• MRI imaging with evidence of muscle atrophy or diffusion 
abnormalities during the process of fat suppression in the 
posterior thigh, abdominal or paravertebral muscles20 (C);
• cardiac arrhythmia associated with skeletal muscle 
weakness21 (C);
• loss or rigidity of aortic compliance and hypertension22 (C);
• idiopathic stroke with middle cerebral artery aneurysms23 (C);
• post-pubertal adolescent or adult idiopathic scoliosis24 (C);
• rigid spine syndrome25(C).
Differential DiaGnosis
Early involvement of respiratory muscles anticipating 
muscle weakness may differentiate PDJ-A from other neuro-
muscular diseases17.
Table 3 lists the diseases considered in the differential di-
agnosis of PDJ-A.
DiaGnostic laboratory MethoDs for 
jUvenile anD aDUlt PoMPe Disease
Dry blood spot on filter paper as a screening test for PD
The introduction of the dry blood spot (DBS) test on fil-
ter paper into clinical practice provided a simple and reliable 
laboratory method for screening patients with suspicion 
of PD26,27 (Table 4).
Whenever the suspicion of PD persists, the test should 
be repeated, and additional diagnostic methods should be 
employed (Table 4). As all screening tests, suspected cases 
require a confirmation by at least one diagnostic test26,27 (B, C). 
DBS pre-analytical problems may result in false-negative 
and/or false positive screening results26.
laboratory diagnosis for childhood and adult PD
Upon a positive DBS screening test for PD, additional 
diagnostic evidence should be obtained by measuring the Table 2. Summary of the main clinical features of adults with 
Pompe disease2,8,9.
Organ or system Clinical features
Skeletal muscle Weakness of the pelvic and shoulder girdles
Myalgia
Exercise intolerance and fatigue
Axial muscle weakness: abdominal and 
lumbar paraspinal muscles
Contractures and deformities (“idiopathic” 
rigid spine)
Other muscles
(facial, oral)
Tongue weakness
Macroglossia
Eyelid ptosis
Dysphonia
Dysphagia
Difficulty in chewing
Lung Dyspnea on exertion
Orthopnea
Acute respiratory failure
Central and obstructive sleep apnea
Sleep disorder - morning headache
Other systems Hepatomegaly
Ectasia of the cerebral arteries with vascular 
aneurysm
Wolf-Parkinson - White syndrome
Postprandial pain in the elderly
Chronic diarrhea
Hyperlordosis and/or scoliosis
Outcomes Adults with PD have a respiratory disturbance 
often before the muscle weakness
Slow progression of motor weakness
Disease progression with stability for long periods
Patients with early respiratory insufficiency may 
have a worse prognosis
Table 3. Differential diagnosis in Pompe disease2.a 
www.musclegenetable.org
Neuromuscular disorder Disorder
Muscular dystrophies Girdle muscular dystrophies
Duchenne e Becker muscular 
dystrophies 
Miofibrilar myopathy
Myotonic Distrophy type 2
Inflammatory myopathies Polymyositis
Congenital myopathies b Nemaline myopathy
Central Core or Multiminicore 
myopathy
Centronuclear myopathy
Danon disease
X-linked myopathy with na 
excesso f autophagy
Metabolics myopathies Glycogen debranching enzyme 
deficiency (Glycogenosis Type IIIa 
ou IIIb – Cori or Forbe disease)
Glycogen branching enzyme 
deficiency (Glycogenosis Type 
IV – Andersen Disease)
McArdle syndrome
Mitocondrial myopathiesc
Motor neuron disease Spinal mucular atrophy Types 2 e 3
Neuromuscular junction disease Miastenia gravis
Congenital myastenic syndromesc
arefers primarily to the late onset PD form; bcongenital myopathies can 
simulate either early onset as late onset PD; crefers primarily to the early 
onset PD form.
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amount of GAA activity in leukocytes or fibroblasts26 and/or 
by conducting GAA genotyping in search of two pathogenic 
GAA mutations2 (Table 4).
Whenever there is any doubt in the DBS test and clinical 
suspicion persists, patients with symptoms suggestive of PD 
should have their GAA activity measured once again by the 
same laboratory that performed the first analysis. If the pa-
tient is negative for the GAA enzyme assay in leukocytes and 
the possibility of PD persists, diagnosis should proceed with 
at least one of the following three options:
a) DNA analysis searching for pathogenic mutations in 
the GAA gene2; or
b) Muscle biopsy evaluation, to assess the presence of 
abnormal accumulation of glycogen with vacuolar myopathy5,29 
(B), although not specific for PD; or
c) Fibroblast culture from skin biopsy to test for GAA activity26.
Genetic asPects of jUvenile anD aDUlt PoMPe 
Disease Patients – GenotyPe-PhenotyPe 
correlation anD criM statUs
The enzymatic deficiency in PD is caused by pathogenic 
mutations in both alleles of the GAA gene. Mutations can be 
similar (homozygote); or, different (compound heterozygote); 
however, both within the GAA gene. The most common mu-
tation observed in PDJ-A patients, including Brazilians, is the 
intronic alteration c.-32-13 T > G (IVS1-13T > G), which is ob-
served in more than two-thirds of the patients worldwide7,30. 
The type and combination of these mutations will determine 
the amount of residual GAA activity in the cells6,7.
The combination of two severe mutations leads to a com-
plete lack of GAA protein and, as a consequence, an extremely 
low residual GAA activity (< 1%); such genotype is associat-
ed with the severe early onset PD31. From an immunological 
point of view, these individuals are classified as CRIM (Cross 
Reactive Immunological Material) negative patients. CRIM 
negative individuals who undergo ERT with GAA (rhGAA en-
zyme) may have severe reactions to the infusion, as well as 
the production of high titers of IgG antibodies32. (B)
On the other hand, any other combination of mutations, 
being at least one of then considered a “milder” mutation, 
such as the classic c. -32-13 T > G, enzyme production will oc-
cur, even if abnormally, resulting in different levels of residual 
GAA activity of up to 30% of the normal value6,7. Patients with 
at least one mild mutation constitute most cases of juvenile 
and late-onset PD and present a clinical phenotype with a 
slower progression1,7. From an immunological standpoint, 
these patients are classified as CRIM positive31, and gener-
ally, will probably not be prone either to severe adverse reac-
tions to Enzyme Replacement Therapy (ERT) with the rhGAA 
enzyme or sustain high titers of antibodies33 (B).
enzyMe rePlaceMent theraPy in Patients 
with chilDhooD anD aDUlt PoMPe Disease
Until recently, treatment for PD consisted only in pal-
liative care. In a natural history study of 255 patients with 
DPJ-A, disease severity assessed by the need for a wheelchair 
or dependence on mechanical ventilation showed that pro-
gression to wheelchair use increased, on average, 13% each 
year in patients without ERT treatment34 (B).
In 2007, the commercial use of the rhGAA enzyme was 
approved for early onset PD patients; and, in 2010, for the 
late-onset PD presentation. In the 18-month clinical tri-
al conducted with the rhGAA enzyme in the late-onset PD 
form, there was an increase in the six minute walk test as well 
as stabilization of their pulmonary function35 (A).
The goals of rhGAA enzyme therapy depend on the stage 
of disease progression35,36 (B), and include:
• To slow down, stabilize or reverse disease progression;
• To reduce comorbidities and increase survival;
• To improve mobility, preserve motor function, delay the 
need for walking assistance, and promote motor gains;
• To improve or maintain respiratory function, thus 
preventing the need for respiratory assistance;
• To improve or preserve patient independence and quality 
of life.
A systematic review37 of the clinical and therapeutic 
outcomes of ERT with the rhGAA enzyme after one year of 
treatment in 251 patients with the PD-A presentation and 
27 patients with juvenile PD yielded the following findings:
• six-minute walk test: 78% increased the distance 
covered, 8% maintained the same distance, and 4% 
decreased the distance;
• Motor Performance: 10% improved, one bedridden 
patient was able to sit up, three patients in wheelchairs 
Table 4. Recommendations for diagnostic tests in Pompe disease in adults26.
Screening Test – DBS – “dried blood spot” on filter paper to perform enzymatic activity analysis of acid α-glucosidase (GAA)a,b
“Gold standard” Diagnostic Test – in fibroblasts or muscle tissue for acid α-glucosidase (GAA) enzymatic assay
Diagnostic Test – molecular analysis of the GAA geneb
Diagnostic Test in DBS – GAA activity in lymphocytes and/or leucocytes
a In clinical practice, the definitive diagnosis of Pompe disease is now being based on the molecular analysis of the GAA gene for the presence of two pathogenic 
allelic mutations (www.pompecenter.nl); bGenetic variants of the GAA gene [c. (1726A; 2065A)] have been identified, especially in Asian populations; the 
combination with a pathogenic GAA allelic pathogenic mutation reduces the GAA enzyme activity on enzymatic assays specially from filter papers, which 
leads to false positives results considering neonatal screening programs. Such individuals are not diagnosed with PD and are instead classified as being 
pseudo-deficient individuals for the GAA enzyme.
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were able to walk a few times a day, and three patients no 
longer required wheelchairs;
• Forced Vital Capacity (FVC) (127 patients): 53% improved 
and 33% worsened;
• Ventilatory support (58 patients): 70% improved.
The delay between the first symptoms of the disease, the 
definitive diagnosis of DPJ-A, and the beginning of ERT, have 
shown an inverse relationship with the therapeutic prognosis 
and clinical outcomes desired38.
Practical instructions for enzyme replacement therapy
Currently, there is only one commercially avail-
able product for ERT with the rhGAA enzyme for PD 
(Reg MS: 1.2543.0020.001-0.)
Regardless of the PD type, treatment with the rhGAA en-
zyme should be started at a reference hospital where it would 
be possible to intervene in the event of any adverse event re-
lated to the venous infusion39. It is also essential to inform 
the family about the goals of ERT, the treatment expectations 
based on the stage of the disease, and the guidelines for clini-
cal follow-up and evaluation28,40.
Health professionals should address the difficulty of 
predicting the response to long-term ERT treatment and 
prioritize factors that could potentially influence treatment 
response, such as respiratory function and muscle involve-
ment. The multidisciplinary team should be instructed 
regarding these issues. We recommend training the nursing 
and pharmacy staff on the handling of the drug prior to the 
first infusion, and provide specific guidance to physicians 
and the infusion center staff. One should always record the 
occurrence of any adverse event, whether or not they are as-
sociated with ERT. The dose of rhGAA enzyme for ERT should 
follow the manufacturer’s recommendations. The current 
standard dose of Myozyme® is a minimum four-hour infusion 
of 20mg/kg every 15 days.
While adverse events in patients with PDJ-A are considered 
rare (see Genotype-Phenotype correlation)39, infusion-related 
reactions generally require medical intervention. These reac-
tions are usually mild to moderate and respond positively to 
a reduction in infusion rate.
The most serious and rarely observed side effects of ERT with 
rhGAA are life-threatening anaphylactic reactions, serious aller-
gic reactions and immune-mediated reactions. Such events are 
also rare in late-onset PD because patients are CRIM positive32.
inclusion and exclusion criteria for enzyme 
replacement therapy (table 5)
The heterogeneity of symptoms and signs present in PD 
patients (Table 2), the intra-familial variability and differ-
ent stages of PD have led to the characterization of different 
patient groups and created a clinical dilemma of when to 
put a patient on ERT with rhGAA. The groups currently are 
identified as newborns identified via newborn screening8; 
asymptomatic patients with or without clinical signs of the 
disease41; symptomatic PD patients36 and patients with se-
vere PD9,10 (Table 5).
Table 5. Summary of recommendations for ERT treatment based on the stage and severity of Pompe disease.
Asymptomatic patients without objective clinical signs
Patients should be examined for proximal muscle weakness and lung function (Pompe registry recommendations, www.registrynxt.com/).
ERT should be considered if:
Symptoms appear
Appearance of proximal muscle weakness and/or > 10% drop in sitting-supine forced vital capacity
Asymptomatic patients with objective clinical signs
ERT should be considered if:
Patient is asymptomatic with muscle weakness detectable by directed examination
Typical vacuolar muscle biopsy
> 10% drop in sitting-supine forced vital capacity 
Symptomatic patients
Enzyme replacement therapy should be considered if:
> 10% drop in sitting-supine forced vital capacity; or increased muscular weakness; with or without ventilatory support
Patient has difficulty conducting daily routine tasks 
Severe patients
If the patient is confined to a wheelchair and using continuous invasive ventilation:
ERT is recommended for 01 year, followed by evaluations to assess therapy effectiveness
After 01 year of ERT, the multidisciplinary team will review the treatment case-by-case, especially for patients requiring continuous 
invasive ventilation
ERT will be continued if there is stabilization or improvement of severe signs and symptoms 
ERT duration
Annual reassessment to review the effectiveness of treatment
Monitoring
Patients receiving enzyme replacement therapy should have IgG antibody levels monitored every 03 months for up to 02 years, and 
then annually (www.registrynxt.com)
ERT: enzyme replacement therapy.
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In most cases of PDJ-A, the duration of rhGAA treatment 
is indefinite. Thus, the treatment goals, the timing of clinical 
evaluations, and quality of life studies (SF-36 - www.sf-36.org/), 
may support the multidisciplinary team in clinical manage-
ment decisions28,40,41. It appears that major improvement of 
muscle strength and respiratory function with ERT is not 
common in patients with late-onset Pompe’s disease35. The 
termination of ERT can be a very difficult task, and there is 
no consensus regarding this topic except on a case-by-case 
discussion. The involvement of family members in such deci-
sions is very important28,40 (Table 5).
Monitoring and laboratory tests for enzyme 
replacement therapy
PD patients on ERT with the rhGAA enzyme will make 
seroconversion in 95% of cases becoming IgG positive39. 
However, exceptionally high titers of persistent antibodies 
may occur and this can activate the complement cascade 
and neutralize the rhGAA enzyme32. In these circumstances, 
there is a decline of the therapeutic response to ERT (walk-
ing, lung function, SF-36) and adverse events associated to 
ERT may be observed32 (B). Currently, immune modulation 
and immune suppression protocols, in an attempt to reduce 
neutralizing antibodies against rhGAA, have been successful-
ly applied in infantile onset PD patients with high sustained 
IgG antibodies42. Patients with PDJ-A are CRIM-positive and 
therefore are less likely to have such serious immunological 
reactions32. The concentrations of IgG and IgE antibodies, 
tryptase and complement activation studies need to be mon-
itored based on the Doctor’s Guide to Clinical Management 
of Pompe Disease.
Hypersensitivity to the drug should be considered an ab-
solute contraindication to the use of ERT with rhGAA enzyme.
Pregnancy, lactation and enzyme replacement 
therapy
Since the introduction of ERT, a growing number of 
women with metabolic diseases have been able to reach 
reproductive life and become pregnant. Pregnant women 
with Gaucher, Fabry and (more recently) Pompe disease, are 
creating a new clinical challenge for obstetricians43,44.
Until 2014, two cases of pregnant women with PD receiv-
ing ERT have been published44,45. Recently, Karabul et al.46 col-
lected information on 52 women with PD-A and 125 pregnan-
cies through a retrospective self-administered questionnaire 
sent to Pompe associations in England and Germany, as well 
as neuromuscular disease centers in Germany. Pregnant 
women undergoing ERT not exhibited a reduction in mobil-
ity and muscle function, and many asymptomatic patients 
experienced their first PD symptoms during pregnancy51. 
Many pregnant women also used wheelchairs intermittently. 
A decrease in lung function, as measured by spirometry, was 
common to all pregnant women, including those undergo-
ing ERT. Nonetheless, the reported experiences were highly 
favorable to the use of ERT during pregnancy, anesthesia, 
postpartum, newborn health, lactation and recovery of pre-
pregnancy clinical status46. FDA classification/pregnancy 
category B (http://www.accessdata.fda.gov).
Pregnant women with neuromuscular diseases and vital 
capacity < 1l (normal reference = 4.5l) should be warned of 
the high risk of complications during pregnancy and child-
birth. In case of maternal hypoxia with O2 saturation under 
85%, the rate of live births is only 12%. The recommendation 
for pregnant women with PD is a cesarean delivery under lo-
cal instead of general anesthesia47.
MUltiDisciPlinary clinical MonitorinG
Due to the predominance of muscular signs and symp-
toms, PDJ-A is primarily a neuromuscular disease. Thus, the 
neurologist’s role is crucial in coordinating the clinical deci-
sions made by the professional health team2,28,40.
The ICD-10 classification (E74.0) may not accurate-
ly describe the functional impairment and disability as-
sociated with PD, since these patients vary in their de-
gree of functionality. The International Classification of 
Functioning, Disability and Health (ICF)48 provides more 
meaningful information and data for clinical purposes 
(Table 6).
A study of 210 adults with PD using the Quality of Life 
Scale (SF-36) survey34 highlights the impact of the dis-
ease on patients’ ability to work, perform household ac-
tivities and move independently outside of their home. 
Progressive disability also increases the dependence of 
family members and other supportive care in the manage-
ment of PD patients.
We recommend using disability scales (the Rotterdam 
study), visual analog scales for measuring pain, and the SF-36.
Table 6. Classification of functioning, disability and health (ICF) 
for adult Pompe disease (2003). www.who.int/classification/icf
Code Domain
b134 Sleep functions
b3100 Voice production
b445; s430 Respiratory muscle functions; structure of the 
respiratory tract
b455 Exercise tolerance functions
b510 Food intake functions
b525 Defection functions
b530 Weight maintenance functions
b730 Muscle strength functions
d230 Performing daily routines
d450 Walking
d460 Moving through different locations
d598 Self-care
d640 Performing household chores
e120 Products and technologies to facilitate mobility 
and/or transport the person indoors and outdoors
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functional rehabilitation of skeletal muscles
Skeletal muscle involvement in PD is characterized by 
progressive weakness, poor posture and compensatory 
movement patterns. Table 7 lists the main recommendations 
for patients with PDJ-A regarding the maintenance of func-
tional muscle activity.
The assessment of skeletal muscle function, strength and 
structure should include:
• Timed functional tests and mobility scales: 6-minute 
walk test; 4-step ascent and descent staircase test40,49;
• Manual or quantified evaluation of muscles strength 
(MRC scale)49;
• Evaluation of tongue strength13;
• Magnetic resonance imaging of the skeletal muscle, 
including tongue, paraspinal and thighs20.
active physical activity
Recent evidence shows that people with carbohydrate 
processing disorders can benefit from light exercise50 (C). 
People who are physically fit are better able to use alter-
native sources of fuel for energy. Excessive strain in PDJ-A 
can cause muscle injuries; therefore, all exercise pro-
grams should be supervised by a professional familiar with 
PD (Table 6).
Therapeutic exercise should start lightly, be interspersed 
with rest periods, and follow a gradual increase in intensity 
until it reaches 60-75% of maximum effort in three to five 
days per week50 (B). Strenuous or eccentric physical thera-
py exercises should be avoided, especially in proximal mus-
cles, flexors and abductors of the lower limbs (Nascimento, 
Siqueira and Barone, personal observation, 2014).
Optimization of the biomechanical advantages of movement:
• Provide positioning and support to increase biomechani-
cal advantage;
• Save energy;
• Optimize the effects of gravity;
• Consider positions that improve the muscle 
length-tension relationship
• Minimize muscle contracture.
Prevention of secondary musculoskeletal deficits 
(table 7)
Secondary musculoskeletal impairments can be prevent-
ed by following the principles of biomechanics to counter-
act deforming forces. This is done by applying light pressure, 
stretching, practicing posture correction, performing orthot-
ic interventions, and using seating and support systems51.
Recent studies show that the mobilization and utilization 
of fat and carbohydrates in skeletal muscles during exercise 
are normal in PD. In fact, the reduction in exercise capacity re-
sults from muscle weakness and wasting and not from a re-
duction of muscle glycogenolysis, even with ERT therapy51 (B).
Pulmonology
Respiratory failure is a major cause of mortality and 
morbidity in PDJ-A10,11,17 (B). Approximately 60% of individu-
als with PDJ-A show a slight decrease in vital capacity (less 
than 80% of normal) and 30-40% show a moderate decrease 
(less than 60% of normal)10,11 (C). Observational studies have 
shown average annual declines in FVC of 1.7% to 4.6%11 (B).
As PDJ-A progresses, muscles weaken and lung vol-
ume is reduced. Consequently, cough can become harmful, 
Table 7. Summary of recommendations for the evaluation and rehabilitation of the musculoskeletal system in juvenile and adult 
patients with Pompe disease.
Include the patient in the International Pompe Registry (www.registrynxt.com/) 
Physical examination and evaluations
Evaluation by a cardiologist and pulmonologist prior to physical therapy and aerobic exercise
Baseline 6-minute walk test (ATM Statement, 2002; www.registrynxt.com).
Annual densitometry (DEXA) (even for patients in wheelchairs)
PD patients with reduced bone density: assessment by specific tests and endocrinologist
Walking assistance equipment to reduce falls
Physical/occupational therapy
Physical therapy program including walking, treadmill, bicycle, hydrotherapy, swimming, muscle strengthening for neuromuscular diseases;
Avoid extreme exercise, excessive fatigue and immobility
Emphasis on aerobic exercises
Incorporate into daily functional activities
Instruct the patient to monitor heart rate and breathing during exercise
Daily exercise regime for the prevention of contractures
Managing contractures
Orthotic devices to prevent joint contractures with posture assessments while the patient is in the wheelchair and support for when 
he/she stands
Surgical intervention
Surgical intervention for scoliosis when the Cobb angle is between 30° and 40°
Vitamin and Mineral supplements 
Vitamin D, calcium and bisphosphonates following the osteoporosis manual
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blood-gas values become abnormal, and respiratory condi-
tions may disrupt sleep52,53.
The guidelines for monitoring and treating pulmonary as-
pects of PD include52,53 (C):
• Clinical evaluation of respiratory status by a pulmonolo-
gist experienced in the clinical management of patients 
with neuromuscular diseases;
• Evaluation of pulmonary function and blood gas analysis 
at diagnosis, annually, at each medical visit, or as changes 
occur in the course of the disease;
• Update the immunization record, including influenza 
and pneumococcus;
• Frequent removal of secretions from the lung airways 
(cough devices, aspiration);
• Assess the use of the cough-assist device and 
train/educate patients and families about its use and 
muscle inhalation techniques;
• Evaluation of respiratory function during sleep if the 
patient feels sleepy during the day, presents with un-
explained fatigue, sleep apnea, morning headaches, or 
when his/her vital capacity falls below 40-50% of normal;
• Treat sleep disorders with positive airway pressure (CPAP) 
or with non-invasive nocturnal ventilation (BiPAP);
• In the absence of sleep studies, consider BiPAP ventilation 
if PCO2 is ≥ 45 mm Hg, or supine forced vital capacity < 50% 
of predicted, or negative forced inspiration < 60 cm H2O, 
or oxygen saturation is < 88% for more than 05 continu-
ous minutes during sleep;
• Aggressive treatment against all lung infections, and con-
comitant diseases sucah as asthma and cardiomyopathy;
• Consider enzyme replacement therapy with recombinant 
human GAA.
For pregnant PD women clinical caution is vital regarding 
the pulmonary and muscle functions (see 7.4 Pregnancy, 
lactation and enzyme replacement therapy).
nutritional and gastrointestinal evaluation and 
treatment
PD patients have difficulty swallowing and eating. Factors 
contributing to this difficulty include facial hypotonia, mac-
roglossia, weakened tongue muscles, and impairment of oral 
movements. Patients have difficulty dealing with saliva and 
secretions usually accumulate on the vocal cords, which 
can also lead to respiratory complications. They experience 
fatigue of the jaw muscles as well as difficulty chewing and 
eating certain foods. For these reasons, patients with PD of-
ten consume low amounts of vitamins, minerals and energy, 
resulting in malnutrition and the compensatory use of mus-
cle proteins, in addition to increased risk of microaspirations 
and aspiration pneumonia by vomiting or regurgitation. 
Also, nutritional problems arising from gastrointestinal 
muscle weakness may also be present, including dysphagia, 
gastroesophageal reflux, gastroparesis, and decreased bowel 
movements leading to constipation.
Patients should be assisted by a group of professionals 
that includes: a speech therapist, a stomal therapist, a psy-
chologist, a dietitian and a nutrition specialist (preferably 
with experience in metabolic diseases) to ensure proper 
nutritional care. Diets and food consistency should be reas-
sessed regularly.
For patients with PDJ-A, the main goal of the diet - other 
than adequate nutrition - is to control glycogen accumula-
tion and the processing of amino acids. We recommend a 
high protein diet (20-25% of total energy intake from protein, 
30-35% from carbohydrates and 35-40% from lipids), with 
special attention to vitamins and minerals, and modification 
of food consistency. Diets rich in protein and/or L-alanine 
and low in carbohydrates have shown positive results in 
PDJ-A. Supplement with 1.4 g of L-Alanine up to 04 times a 
day is indicated if the recommended protein content associ-
ated with 4% (500 ml) of branched-chain amino acids cannot 
be met. Results are optimized with training and physical ac-
tivity. Body composition measurements include body mass 
index (kg/m2) calculation, waist circumference and/or pli-
cometry and Dual-energy X-ray absorptiometry (DXA).
Approaches to gastrointestinal problems include postur-
al swallowing techniques, swallowing maneuvers to improve 
facial muscle coordination (supraglottic, Mendelsohn 
maneuver), environmental modifications, and oral senso-
ry awareness techniques. The use of a feeding tube (nasal 
tube, gastrostomy or gastrojejunostomy tube) should also 
be considered.
swallowing
In PD patients with dysphagia, positive results have been 
obtained with a soft diet consisting of purees and similar 
preparations, and including the use of thickeners.
Percutaneous endoscopic gastrostomy (PEG) is a surgical 
endoscopic procedure that aims to provide extended food ac-
cess for patients with an intact and functional gastrointesti-
nal tract, but who are unable to maintain adequate oral en-
ergy intake54. PEG is indicated for PDJ-A patients with severe 
dysphagia, aspiration risk, weight loss (>10% in one year) and 
FVC < 40%54. The Brazilian Ministry of Health established 
(Portaria GM/MS No. 343e No. 120) mechanisms for the imple-
mentation of assistance centers and high complexity reference 
centers for nutritional therapy as part of SUS (Sistema Único 
de Saúde), and established their technical and operational 
requirements (procedure code 98.003.02-0). Gastrostomy in-
volves a laparotomy and often general anesthesia, which limits 
its use in patients with severe PDJ-A (see Anesthesia/Surgery). 
The main indication of PEG in daily clinical practice is for long-
term enteral nutrition for patients with dysphagia54.
anesthesia/surgery
The medical staff must carefully attend to a series of consid-
erations when indicating surgery to patients with PD, because 
the increase risk of complications involving anesthesia55 (B/C).
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Patients with neuromuscular diseases due to metabol-
ic causes may have a higher risk of adverse events to gen-
eral anesthetics, especially the combination of halothane 
and succinylcholine55.
The following guidelines are recommended for surgery 
procedures in PDJ-A:
• Conduct anesthetic procedures only when necessary;
• Consolidate all surgical procedures requiring anesthesia 
to reduce the risk of exposure to the anesthetic;
• Avoid tracheal intubation and, if indicated, make sure it is 
performed by an experienced professional;
• Conduct rigorous intraoperative supervision;
• Use inhalation agents in non-severe patients;
• Avoid depolarizing agents due to the risk of severe 
hyperkalemia;
• Monitor circulating fluid volume;
• Whenever possible, perform surgery in centers with pro-
fessionals experienced with PD.
family history and genetic counseling
PD is an autosomal recessive disease caused by patho-
genic mutations in both alleles of the GAA gene1,7. Parents 
of individuals with PD are healthy obligatory heterozy-
gotes with a risk of PD recurrence in their future offspring 
of approximately 25%. Therefore, once an individual is 
diagnosed with PD, it is essential for parents to receive 
genetic counseling. The diagnosis of an individual with 
PD justifies the active search of the disease among his/
her siblings. Asymptomatic or mildly symptomatic cases 
are often identified due to the intrafamilial clinical vari-
ability observed between two siblings with PD. Laboratory 
screening and diagnostic methods are the same as for the 
index case (Table 4).
Individuals with PDJ-A have benefited from ERT, with in-
creased survival rates. As a result, some of them may have 
families once they reach reproductive age, especially those 
who are mildly symptomatic or diagnosed with late PD. An 
individual with PD can have an affected child if his/her part-
ner is heterozygous for mutations in the gene that causes the 
disease. Pregnant women with PD require intensive supervi-
sion (see Pregnancy).
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